POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL.

Authors :: Luminari, S.
Marcheselli, L.
Manni, M.
Anastasia, A.
Vitolo, U.
Chiarenza, A.
Rigacci, L.
Angelucci, E.
Fama, A.
Pulsoni, A.
Rattotti, S.
Angrilli, F.
Gaidano, G.
Stelitano, C.
Bertoldero, G.
Cascavilla, N.
Salvi, F.
Ferreri, A.J.
Tarantino, V.
Bellei, M.
Source :: Hematological Oncology; Jun2017 Supplement, Vol. 35, p228-229, 1p
Publication Year :: 2017

Full Text Access

Tools